Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008968 | 0.90 | ACACB (0.50) | PRMT5WDR77ACACBFFAR4NOTUM | |
| SCHEMBL20012514 | 0.85 | PRMT5 (0.45) | PRMT5WDR77ACACBFFAR4RORC | |
| SCHEMBL10509100 | 0.82 | PRMT5 (0.45) | PRMT5WDR77ACACBFFAR4NOTUM | |
| SCHEMBL19368164 | 0.79 | NOTUM (0.44) | PRMT5WDR77NOTUMMBTD1L3MBTL3 | |
| SCHEMBL6621520 | 0.76 | CYP2D6 (0.57) | PRMT5WDR77ACACBFFAR4NOTUM | |
| SCHEMBL20008964 | 0.75 | BCHE (0.57) | CYP2D6 | |
| SCHEMBL348868 | 0.75 | ACACB (0.54) | PRMT5WDR77ACACBFFAR4NOTUM | |
| SCHEMBL13056 | 0.73 | MAPT (0.52) | NOTUMMBTD1L3MBTL3L3MBTL1HTT | |
| SCHEMBL10662242 | 0.73 | MAPT (0.52) | NOTUMMBTD1L3MBTL3L3MBTL1HTT | |
| SCHEMBL12919 | 0.73 | MAPT (0.52) | NOTUMMBTD1L3MBTL3L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | PRMT5 282/4885WDR77 56/4885ACACB 3506/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | PRMT5 282/4885WDR77 56/4885ACACB 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.